A study conducted at the State University of Campinas (UNICAMP) in Brazil investigated the process of muscle pain ...

Top-line results from two pivotal Phase III trials found that MR-107A-02 significantly reduced pain intensity following ...

Topline data were announced from 2 phase 3 trials evaluating MR-107A-02 for the treatment of moderate to severe acute pain.

Viatris (NASDAQ:VTRS) stock rises 5% premarket as Phase 3 trials show success for non-opioid pain therapy, meloxicam as a ...

Dogwood Therapeutics, Inc. commenced dosing of patients in the Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b ...

A version of meloxicam designed to work faster has beat out a placebo in two late-stage studies focused on post-surgical ...

Agents that target NaV1.8, a voltage-gated sodium channel, are showing promise. The FDA approved one of them, Journavx ...

Good morning, everyone, and welcome to the Viatris Q1 2025 earnings call. (Operator Instructions) Please also note, today's event is being recorded. At this time, I'd like to turn the floor over to ...

Viatris shares favorable Phase 3 data for contraceptive patch and pain drug, affirms 2025 sales, and raises adjusted EPS ...

Intervertebral disc disease (IVDD) occurs when discs bulge or burst, compressing the spinal cord. 1 Symptoms range from pain ...